Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Astrocytic 4R tau expression drives astrocyte reactivity and dysfunction
Lubov A. Ezerskiy, Kathleen M. Schoch, Chihiro Sato, Mariana Beltcheva, Kanta Horie, Frank Rigo, Ryan Martynowicz, Celeste M. Karch, Randall J. Bateman, Timothy M. Miller
Lubov A. Ezerskiy, Kathleen M. Schoch, Chihiro Sato, Mariana Beltcheva, Kanta Horie, Frank Rigo, Ryan Martynowicz, Celeste M. Karch, Randall J. Bateman, Timothy M. Miller
View: Text | PDF
Research Article Neuroscience

Astrocytic 4R tau expression drives astrocyte reactivity and dysfunction

  • Text
  • PDF
Abstract

The protein tau and its isoforms are associated with several neurodegenerative diseases, many of which are characterized by greater deposition of the 4-repeat (4R) tau isoform; however, the role of 4R tau in disease pathogenesis remains unclear. We created antisense oligonucleotides (ASOs) that alter the ratio of 3R to 4R tau to investigate the role of specific tau isoforms in disease. Preferential expression of 4R tau in human tau–expressing (hTau-expressing) mice was previously shown to increase seizure severity and phosphorylated tau deposition without neuronal or synaptic loss. In this study, we observed strong colocalization of 4R tau within reactive astrocytes and increased expression of pan-reactive and neurotoxic genes following 3R to 4R tau splicing ASO treatment in hTau mice. Increasing 4R tau levels in primary astrocytes provoked a similar response, including a neurotoxic genetic profile and diminished homeostatic function, which was replicated in human induced pluripotent stem cell–derived (iPSC-derived) astrocytes harboring a mutation that exhibits greater 4R tau. Healthy neurons cultured with 4R tau–expressing human iPSC–derived astrocytes exhibited a higher firing frequency and hypersynchrony, which could be prevented by lowering tau expression. These findings support a potentially novel pathway by which astrocytic 4R tau mediates reactivity and dysfunction and suggest that astrocyte-targeted therapeutics against 4R tau may mitigate neurodegenerative disease progression.

Authors

Lubov A. Ezerskiy, Kathleen M. Schoch, Chihiro Sato, Mariana Beltcheva, Kanta Horie, Frank Rigo, Ryan Martynowicz, Celeste M. Karch, Randall J. Bateman, Timothy M. Miller

×

Figure 2

Tau and isoform expressions at protein level measured by mass spectrometry.

Options: View larger image (or click on image) Download as PowerPoint
Tau and isoform expressions at protein level measured by mass spectromet...
(A) Schematics of tau protein, antibody epitopes, and peptides used for mass spectrometry analyses. MTBR, microtubule binding region. (B) hTau astrocytes have approximately 100-fold less tau expression as compared with WT neurons measured by 212-221 mid domain peptide (“Total tau”) that is common to all isoforms, n = 3 biological replicates/group. (C) Three 4R isoform-specific peptides — (a) 282-290, (b) 275-280, (c) 299-317 — that are in R2 region and 1 common peptide (260-267) that is in proximity were measured by quantitative mass spectrometry in ASO-treated hTau astrocytes. The ratio of each 4R-specific peptide to common peptide was calculated in astrocytes (282-290/260-267, 275-280/260-267, 299-317/260-267) and compared with the ratio of saline. 3R to 4R ASO increased 4R-specific peptides 1.53 ± 0.03 fold and 4R to 3R ASO decreased 4R-specific peptides 0.51 ± 0.04 fold compared with saline, n = 3 biological replicates/group.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts